ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Go back to ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
(NASDAQ: IBRX) Delayed: 7.28 -0.08 (1.09%)
Previous Close $7.36    52 Week High
Open $7.49    52 Week Low
Day High $7.55    P/E N/A 
Day Low $7.18    EPS
Volume 3,484,575